Napsec

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Napsec

Property Description
Active Ingredients Naproxen Sodium, Esomeprazole Magnesium
Form Delayed-release combination tablet
Pharmacological Class Nonsteroidal Anti-inflammatory Drug (NSAID) and Proton Pump Inhibitor (PPI)
General Purpose Managing pain and inflammation while providing gastric protection
Origin Synthetic

What Type of Medicine is Napsec?

Napsec is a fixed-dose combination product taken via the oral route, classified within two distinct pharmacological groups: Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Proton Pump Inhibitors (PPIs). This dual classification results from its two active components, Naproxen Sodium and Esomeprazole Magnesium. This specific fixed-dose combination, also known by the brand name Vimovo, is clinically recognized for optimizing patient tolerability compared to taking the NSAID alone. This preparation is a combination drug where the NSAID component is co-delivered with an agent designed to reduce stomach acid secretion. The medication is presented as a delayed-release combination tablet that is engineered for sequential action in the digestive tract.

Active Components and General Purpose

The medication’s core composition involves the combination of two synthetically derived active ingredients. Naproxen Sodium is included to address symptoms such as pain and stiffness, while Esomeprazole Magnesium acts as an antisecretory compound. The general therapeutic purpose of this formulation is to address symptoms associated with inflammation and pain while mitigating the risk of damage to the stomach lining. This combination strategy is an established approach for reducing the incidence of gastrointestinal complications commonly associated with NSAID use. This formulation is designed to deliver effective pain relief while structurally lowering the risk of gastric irritation, directly connecting its composition to a reduced gastrointestinal vulnerability.

What side effects are possible with Napsec?

Possible Side Effects and Safety Information

The official safety characteristics of Napsec are defined by the documented risks of both the Nonsteroidal Anti-inflammatory Drug (NSAID) and the Proton Pump Inhibitor (PPI) components, as classified by regulatory authorities.

Adverse Reactions and System Classification

Adverse reactions are grouped by the affected body system, with many classified by frequency. Common adverse reactions officially listed in regulatory documents often involve Gastrointestinal Disorders (including gastritis, diarrhea, dyspepsia, upper abdominal pain, and nausea) and Nervous System Disorders (such as headache and dizziness).

Other system-organ classes involved include Cardiovascular Disorders, Renal Disorders, and Dermatological Reactions.

Serious Adverse Reactions

The labeling includes prominent statements regarding the potential for two serious, life-threatening risks inherent to the NSAID component:

  • Serious Gastrointestinal Adverse Events: The risk of severe gastrointestinal complications, including bleeding, ulceration, and perforation of the stomach or intestines, which may occur without warning.
  • Serious Cardiovascular Thrombotic Events: The potential for an increased risk of serious cardiovascular events, including Myocardial Infarction (heart attack) and Stroke.

Long-term PPI exposure may also be officially associated with risks like bone fractures and vitamin B-12 deficiency.

Population-Specific Safety Considerations

The official prescribing information contains specific limitations for certain groups. Use is contraindicated in women starting at 30 weeks gestation (third trimester of pregnancy). Furthermore, older adults are at a greater documented risk for serious gastrointestinal and cardiovascular adverse events. The medicine is not recommended for use in individuals with moderate or severe renal impairment or severe hepatic insufficiency.

Official safety notes state that the risk of serious cardiovascular and GI events may increase with the duration of use.

Overdose and Emergency Response

The official regulatory description of Napsec overdose primarily reflects the potential for toxicity from the Naproxen Sodium component. Documented presentations of overexposure commonly include gastrointestinal disturbances such as epigastric pain, nausea, and vomiting, alongside Central Nervous System effects like drowsiness, dizziness, and lethargy.

Overdose carries the risk of severe or life-threatening outcomes, including acute renal failure, metabolic acidosis, and major gastrointestinal bleeding. In extreme cases, severe CNS depression leading to convulsions or coma has been documented. Seek immediate medical attention upon any known or suspected overexposure to Napsec, and contact emergency services immediately if severe symptoms are present.

Management is strictly symptomatic and supportive treatment. The regulatory data confirms that no specific antidote is known for this overdose. Procedures such as gastric lavage and the use of activated charcoal may be considered as part of the management protocol, and correction of fluid and electrolyte abnormalities is often required. Due to the risk of severe complications, hospital monitoring may be necessary, particularly as manifestations may be more severe in patients with pre-existing renal or hepatic impairment.

Therapeutic Uses of Napsec

Quick Facts

  • Targeted Conditions: Management of signs and symptoms related to osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.
  • Additional Use: Provides relief for primary dysmenorrhea.
  • Protective Benefit: Intended to help lower the risk of developing gastric ulcers in individuals requiring nonsteroidal anti-inflammatory drug (NSAID) therapy.

What Napsec Treats: Main Uses and Benefits

Napsec is a combination medication employed for the symptomatic management of certain rheumatological conditions. Its primary therapeutic goal is to address the signs and symptoms associated with inflammatory joint disorders.

This medicine is used for the relief of discomfort, tenderness, and stiffness connected to osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. For adult patients, it is utilized as part of the overall management strategy for these conditions. It is also an established treatment for the relief of pain related to primary dysmenorrhea (menstrual cramps).

An important secondary function is to assist in protecting the upper digestive tract. The formulation is intended for individuals who require ongoing treatment with a nonsteroidal anti-inflammatory drug (NSAID) but are also considered to be at an elevated risk of developing stomach ulcers. This helps mitigate a common concern associated with the naproxen component, supporting continued use where clinically appropriate.

Eligibility and Restrictions for Use

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults for symptomatic relief of inflammatory conditions. Adolescents 12 years of age and older weighing at least 38 kg are approved for Juvenile Idiopathic Arthritis.
Populations for whom use is not recommended Use is not recommended in patients with moderate or severe renal impairment or for the initial treatment of acute pain. Use during lactation (breastfeeding) is generally discouraged.

Contraindicated Populations

Napsec is strictly contraindicated for the following groups:

  • Patients with known hypersensitivity to Naproxen, Esomeprazole, or other NSAIDs (including those with aspirin-sensitive asthma).
  • Women in the third trimester of pregnancy (at 30 weeks gestation and later).
  • Patients with severe heart failure, severe hepatic impairment, or severe renal impairment (creatinine clearance < 30 ml/minute).
  • Individuals with active peptic ulceration or those undergoing treatment for perioperative pain in the setting of CABG surgery.

Age-Related and Conditional Rules

  • Pediatric Use: Safety and efficacy have not been established in children younger than 12 years of age or weighing less than 38 kg.
  • Geriatric Use: Caution is advised for older adults, as they are at a greater risk for serious gastrointestinal events.

The official eligibility profile is defined by a series of absolute contraindications (e.g., severe organ failure, allergy history) and specific restrictions related to age and physiological status. Regulatory documents limit use to eligible adults and adolescents who do not present with any of the formally prohibited clinical states or comorbidities.

What should I know about interactions with other medicines?

Napsec Interactions with other medicines and products

Property Value
Medicinal product categories with documented interactions Other non-aspirin NSAIDs, Anticoagulants, SSRIs, Antihypertensives, HIV Antivirals, Methotrexate, Lithium, CYP inducers.
Specific interacting medicines (if explicitly listed) Atazanavir, Rilpivirine, Warfarin, Methotrexate, Lithium, Clopidogrel.
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic interaction (CYP2C19 inhibition): Affects certain drug metabolism. Pharmacodynamic interaction: NSAID antagonism of antihypertensive effects; Additive risk of bleeding. Absorption alteration: PPI component alters pH-dependent drug absorption.
Timing-based interaction rules (if applicable) Mandatory requirement to take the medicine at least 30 minutes before meals.
Population-specific interaction notes (if applicable) Elderly: Increased unbound plasma fraction of Naproxen. Severe Hepatic Impairment: Avoidance is recommended due to reduced drug clearance.

Interaction Classifications (High-Level)

Property Value
Interaction severity classification (as defined in official documents) Contraindicated Combinations (e.g., specific HIV antivirals, other NSAIDs); Clinically Significant Interactions (e.g., Warfarin, Methotrexate).
Regulatory basis (EMA / FDA / etc.) The interaction profile is established and documented across major government regulatory sources (FDA Prescribing Information and EMA SmPC).

Resulting Interaction Structure

Official interaction statements:

  • The co-administration of this product with Atazanavir or Rilpivirine is formally contraindicated due to the PPI component significantly reducing antiretroviral plasma exposure.
  • Concomitant use with other Naproxen-containing products or non-aspirin NSAIDs is restricted due to the cumulative risk of NSAID-related adverse events.
  • The NSAID component reduces the antihypertensive effect of co-administered ACE inhibitors, ARBs, and Diuretics through a pharmacodynamic interaction.
  • The PPI component is documented to inhibit CYP2C19, affecting the active metabolite formation of Clopidogrel.
  • Co-administration with Warfarin is documented to increase the risk of bleeding complications.

Connection to the overall interaction profile (2–4 sentences): The official interaction profile is defined by the necessity to manage risks originating from the NSAID component, which drives pharmacodynamic interactions related to bleeding and blood pressure control. The PPI component creates pharmacokinetic interactions that alter drug metabolism and absorption, necessitating formal contraindications for certain HIV therapies. The profile also establishes a mandatory timing-based administration rule and population-specific notes for use in the elderly and those with severe hepatic impairment.

Mechanism of Action

Mechanism of Action: How Napsec Works

Napsec utilizes two distinct mechanistic domains to modulate key physiological processes. The first component functions as a potent inhibitor of cyclooxygenase (COX) enzymes, specifically targeting the COX-1 and COX-2 isoforms. This action interferes with the eicosanoid synthesis pathway, resulting in a reduction in the cellular production of prostaglandins. The consequence of this biochemical alteration is the modulation of local signaling intensity across tissues, which influences the body's core thermoregulatory set point and diminishes the sensitivity of peripheral sensory endings.

The second component of Napsec focuses on the regulation of the gastrointestinal environment. This ingredient acts as an inhibitor on the H+/K+-ATPase proton pump located in the parietal cells of the stomach lining. By blocking this transport protein, the drug suppresses the secretion of hydrochloric acid, leading to a lowered hydrogen ion concentration in the stomach lumen (increased pH). This mechanistic activity occurs concurrently with the activity of the first domain.

Dosage and Administration Information

Napsec is administered via the oral route as a fixed-dose, delayed-release combination tablet, available in two strengths: 375 mg/20 mg or 500 mg/20 mg of naproxen and esomeprazole, respectively. The standard regimen for approved adult uses is one tablet twice daily. This twice-daily dosing establishes the necessary schedule for maintaining continuous therapeutic exposure.

For proper administration, the tablet must be taken at least 30 minutes before a meal and must be swallowed whole with liquid. To preserve the intended sequential release of its components, the tablet must not be split, chewed, crushed, or dissolved. This procedural constraint ensures the esomeprazole layer is released first, followed by the naproxen component.

The general use pattern requires administering the lowest effective dose for the shortest duration consistent with treatment goals. Controlled studies for the specific purpose of reducing gastric ulcer risk do not extend beyond 6 months. Usage guidelines advise caution in older adults and state that the medicine should be avoided in patients with moderate to severe renal insufficiency. If a dose is missed, instructions are to skip the missed dose and resume the regular schedule, rather than taking two doses at one time.

Recent Clinical Evidence

Recent Clinical Evidence

Overview of Clinical Trials

Napsec is a combination medication containing an nonsteroidal anti-inflammatory drug (NSAID), naproxen, and a proton pump inhibitor (PPI), esomeprazole. The naproxen component addresses pain and inflammation associated with conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The esomeprazole component is included to manage the risk of developing stomach ulcers associated with prolonged NSAID use.

Efficacy and Tolerability

Clinical research, including systematic reviews and network meta-analyses, has explored the dual-action benefit of this combination therapy.

Studies suggest that Napsec is equally effective as the naproxen component alone and other non-specific NSAIDs in managing the arthritic symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.

Primary Efficacy Findings Upper Gastrointestinal (GI) Tolerability
Efficacy similar to other NSAIDs for arthritic symptoms. Improved GI tolerability compared to the naproxen component and several other NSAIDs used alone.
Approved for symptom relief in patients at risk of NSAID-associated gastric ulcers. Decreased risk of gastric ulcers and related complications was observed in at-risk patients.

Safety Profile

In clinical trials, the combination has shown an improved upper gastrointestinal safety profile compared to the NSAID component alone. The most frequently reported adverse events are often related to the GI tract, such as dyspepsia and abdominal discomfort. In most studies, these events were reported as mild. Patients with known cardiovascular disease or risk factors may face a greater risk of events, which is a known risk for NSAID therapies in general. Regulatory bodies have approved this combination for patients requiring naproxen who are also at risk for NSAID-associated gastric ulcers.

Key Studies & References American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee

Frequently Asked Questions (FAQ)

Common questions about Napsec (FAQ)

Q: How long does the anti-inflammatory effect of one Napsec dose generally last?

The naproxen component of this medicine has a biological half-life, which describes how long the drug remains active, of approximately 12 to 17 hours. This duration is consistent with the established twice-daily administration schedule for maintaining continuous therapeutic levels in the body for its anti-inflammatory effect.

Q: Can Napsec cause changes in blood pressure?

Official warnings state that the anti-inflammatory component (naproxen) may lead to new or worsened hypertension (high blood pressure). Official product information emphasizes the need for blood pressure monitoring during treatment for patients using this medication.

Q: Can Napsec be taken safely alongside low-dose aspirin?

Official product guidance states that co-administration with low-dose aspirin for cardiovascular protection is generally not recommended due to a significantly increased risk of serious bleeding complications in the stomach and intestines.

Q: What does 'NSAID-associated gastric ulcers' refer to in the context of Napsec?

This term refers to the potential for ulcers or internal bleeding in the stomach and intestines that can occur as a serious risk when taking nonsteroidal anti-inflammatory drugs (NSAIDs). The protective component (esomeprazole) is included specifically to manage and reduce this risk, which is known to be associated with the naproxen component.

Q: How long is Napsec typically prescribed for a chronic condition like arthritis?

Clinical trials conducted to establish the benefit of reducing gastric ulcer risk have been limited to a duration of 6 months. In general, regulatory guidance emphasizes using the lowest effective dose for the shortest period of time that achieves the necessary treatment goals for chronic conditions.

Q: What is the difference between the available strengths of Napsec (e.g., 375/20 mg vs 500/20 mg)?

The difference in strengths relates to the amount of the anti-inflammatory component, naproxen, which is either 375 mg or 500 mg. In both available strengths, the amount of the protective component (esomeprazole) remains the same at 20 mg.

Q: Does Napsec use come with a Black Box Warning in regulatory documents?

Yes, the official prescribing information includes a prominent Boxed Warning, the most serious warning required by the FDA. This warning highlights the potential for serious cardiovascular thrombotic events (like heart attack or stroke) and serious gastrointestinal adverse events (like bleeding and ulcers).

Q: Is Napsec a common brand name for the Naproxen/Esomeprazole combination?

This product is a fixed-dose combination of the drugs naproxen and esomeprazole magnesium. It may be available under different brand names, such as Vimovo, or as a generic equivalent, as determined by your local market.

Q: How long does it typically take to feel the initial relief from Napsec?

Because of the delayed-release formulation of the tablet, the absorption of the naproxen component is slower compared to other immediate-release naproxen products. As a result, initial relief from pain may also be delayed compared to immediate-release versions of the anti-inflammatory component.

Q: What is the expected timeline for Napsec to show its full effect on inflammation?

Official information indicates that to achieve the full anti-inflammatory benefit for chronic conditions like arthritis, it may take up to two weeks of taking the medication regularly for the full intended effect to develop.

Q: Is it generally advised to avoid alcohol consumption while taking Napsec?

Official warnings state that the risk of serious stomach bleeding is increased if a patient consumes three or more alcoholic drinks every day while using this product. This is a topic that can be reviewed with a healthcare professional.

Q: What is the information regarding Napsec and concurrent use of other antacid medications?

Since the medication already contains esomeprazole, which reduces stomach acid, the need for additional acid reducers is usually lowered. However, patient guidance suggests that if necessary, antacids can be taken while using this product.

Q: Are there any known interactions between Napsec and herbal supplements?

The official product label specifically documents information regarding the co-administration of St. John’s Wort. Taking this herbal supplement may decrease the plasma concentration of the protective component (esomeprazole), potentially reducing its effectiveness.

Q: What is the guidance on using Napsec for women who are breastfeeding?

Official regulatory documents confirm that both the naproxen and esomeprazole components are known to pass into breast milk. Therefore, the use of the drug while breastfeeding is subject to careful consideration of the risks and benefits.

Q: Is Napsec approved for use in pediatric patients with juvenile idiopathic arthritis (JIA)?

The product is approved for the relief of the signs and symptoms of juvenile idiopathic arthritis (JIA). This approval is specifically for patients 12 years of age and older who meet certain weight requirements and are at risk of developing NSAID-associated gastric ulcers.

Q: Is there a risk of developing a dependency on Napsec?

Napsec is classified as a nonsteroidal anti-inflammatory drug (NSAID) combined with a proton pump inhibitor (PPI). It is not an opioid, and official regulatory information indicates no known risk of physical dependence or addiction associated with its use.

Q: Are there generic versions of the Naproxen/Esomeprazole combination available?

Official sources, including those that list FDA-approved drugs, confirm that generic formulations of the naproxen and esomeprazole magnesium delayed-release tablets are available. These generics are considered therapeutically equivalent to the brand-name product.

Q: What are the proper storage requirements for Napsec tablets at home?

The official product information specifies that the tablets should be stored at controlled room temperature, which is typically between 20 C and 25 C (68 F and 77 F). They should be kept protected from excessive moisture.

Q: Is Napsec used for back pain or muscle sprains?

The product's formal indications are for the relief of signs and symptoms of chronic, inflammatory conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. It is not listed as being approved for use in short-term conditions like general back pain or muscle sprains.

Q: Can Napsec affect fertility?

Official prescribing information states that nonsteroidal anti-inflammatory drugs (NSAIDs) may cause a delay in or prevention of ovulation. This information is relevant for women who are having difficulties conceiving.

How should Napsec be stored and disposed of?

How to Store and Dispose of Napsec (Naproxen/Esomeprazole Magnesium)

The storage and disposal of Napsec must adhere strictly to official regulatory requirements to maintain product quality and safety.

Storage Conditions

  • Temperature and Protection: Store the medicine at room temperature, generally not exceeding 30 C (86 F), and protect it from both moisture and light.
  • Packaging: Keep the medicine in its original package and ensure the bottle is tightly closed.
  • Child Safety: It is mandatory to keep Napsec out of the sight and reach of children.
  • Stability: Do not use the medicine after the expiry date printed on the packaging.

Disposal Instructions

  • Controlled Waste: Do not dispose of unused or expired medicine by throwing it into household waste or flushing it down the wastewater system.
  • Procedure: Ask a pharmacist or local waste management facility for the proper method to dispose of medicines no longer needed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Napsec found in:

A-Z Index: